The Akibah Health offering is now closed and is no longer accepting investments.

Akibah Health

The world's first OtterBox-enabled, smartphone case glucometer!

Akibah Health

The world's first OtterBox-enabled, smartphone case glucometer!

San Jose, CA
Health Tech
GluCase is an all-in-one diabetes management system that seamlessly integrates a glucose monitoring kit and Bluetooth module in a smartphone case. With a monthly subscription, customers receive a GluCase, a monthly test strip supply, and access to a mobile app that provides tips on how to augment their behavior and better manage their condition via predictive analytics.

$72,533

raised
107
Investors
$5.96M
Valuation
$0.56
Price per Share
$99.68
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
0
Days Left

$72,533

raised
107
Investors
$5.96M
Valuation
$0.56
Price per Share
$99.68
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
0
Days Left
This offering ended on April 30, 2020 and is no longer accepting investments.

Reasons to Invest

1 of 2 American adults will be diabetic or pre-diabetic in the coming years (UnitedHealth Group)
The founding team is made up of Cornell grads with deep experience in engineering, intellectual property, and strategic management. Advisor and strategist Larry Ellingson is a former chairman of the American Diabetes Association and leader of global diabetes at Eli Lilly and Company
Techstars-backed, Sprint Corporation-funded, and commercially partnered with the #1 selling smartphone case brand in North America — OtterBox. Akibah Health has produced and shipped its first-generation GluCase system to customers throughout the United States

The world's first OtterBox-enabled, smartphone case glucometer!

Founded by individuals with personal ties to the diabetes community

Development of the GluCase began in a dorm room at Cornell University in response to our self-imposed challenge to drastically improve the lives of our friends and family living with diabetes. After speaking with countless individuals living with Type 1 and Type 2 diabetes, we knew that one way to accomplish our goal would be to simplify the form factor of a traditional, bulky, and burdensome glucose meter kit by integrating it with everyone's most prized and connected possession — the smartphone.

30M Americans suffer from diabetes and are tied to cumbersome, inconvenient treatment solutions

UnitedHealth Group predicts that over half of all American adults will become diabetic or pre-diabetic by 2020. In our experience, existing diabetic monitoring devices are inconvenient, bulky, and unintuitive. Additionally, we believe the data collected around their condition is not being utilized for insights to improve their health.

An all-in-one monitoring system and preventative care - in a smartphone case

Akibah Health’s flagship product, GluCase, empowers people with diabetes to live their lives untethered from bulky meters, cables, and testing supplies. GluCase seamlessly integrates the glucose monitoring kit with a Bluetooth module—all built into the smartphone case. Users can view glucose readings in the context of other actionable information (activity, diet, and medications) and receive real-time coaching from their care team via a mobile app, enabling the delivery of faster and better preventative care.

Globally, 422M live with diabetes

We are initially targeting younger people with diabetes who are partially or non-compliant with regular monitoring to adopt GluCase. 

  • The national cost of diabetes in the U.S. in 2012 was more than $245 billion (CDC)

  • 15% of total medical expenditures are spent on anti-diabetic agents and diabetes supplies  (ADA)

  • 1 out of 3 adults has prediabetes in the U.S. (CDC)

Strategic partnerships with a top healthcare provider and the #1 selling smartphone case brand in North America

We’ve raised $500K via a Techstars-backed Seed Round, built relationships with key players, and partnered with the #1 selling smartphone case brand in North America.

And we are more than just an idea:

  • Sales: We have fulfilled hundreds of pre-order sales in 2018 via the first-run production of the beta GluCase system - through $50K+ on Indiegogo

  • Strategic Partners: We currently have pilots with clinics in the U.S. and Canada and are finalizing a pilot with the top healthcare provider in Michigan, Beaumont Health. 

  • Trend Integration: We’ve secured a commercialization partnership with OtterBox, the #1 selling smartphone case in North America.

Winning amazing awards and joining incredible accelerators

Our fans already love us

And so does the press!

Simplifying diabetes management with GluCase, your convenient smartphone case diabetes-care system

GluCase’s easy smartphone case solution offers real-time, life-saving coaching, and eliminates the need to carry bulky supplies. Patients will pay a monthly subscription to receive a GluCase monitoring device, and they’ll get monthly test strip supplies delivered to their doorstep. They’ll quickly and easily be able to access their mobile app and dashboard - making monitoring diabetes easy. 

The ease of a monthly subscription

Akibah Health will initially target endocrinology and primary care practices where most newly diagnosed individuals receive their glucose meters and visit every three months to review their blood sugar, but GluCase subscriptions will also be offered online. Within their monthly subscription ($29), patients will receive a GluCase, monthly test strip supply of 50-100 strips, and access to the mobile app and dashboard - for additional coaching features, they can sign up for the premium subscription ($59) and receive personalized coaching.

The first all-in-one diabetes solution built into a smartphone case

Akibah Health’s technology is giving individuals with diabetes their first chance at living a life truly untethered. Our search shows, while other companies have tried to bridge the gap between the bulky carrying case and the phone, they still require the individual to carry their testing supplies, universal transfer cables, and/or dongles that attach to the phone - not GluCase. Plus, GluCase correlates changes in glucose levels with information on lifestyle choices - giving individuals tips on how to augment their behavior and better manage their condition via predictive analytics. 

Expanding GluCase to treat patients with heart disease

In just four years, we hope to capture 2.5% of the diabetes management market in the U.S., Mexico, and India. And GluCase also offers more ability to grow. Beyond diabetes management, the GluCase solution can be used to measure and track at-risk heart disease patients by measuring monthly cholesterol levels - an even larger market, in need.

A group with a personal tie to the cause

The team met at Cornell University while completing their studies; they committed themselves to finding a way to improve the lives of people with diabetes after losing several of their loved ones to the condition and watching many others struggle with its complications. They have deep experience in engineering, finance, intellectual property, and the commercialization of health-tech innovations. The Advisory Board is comprised of individuals from top Medical Boards, and are experienced in handling leading health solutions.

We believe investing in Akibah Health positively impacts people’s lives while targeting a large and growing global market

We are backed by one of the top accelerators in the world, Techstars - an organization that only accepts 1% of applicants. GluCase has been through multiple, robust quality control tests in view of product development, design for manufacturability, and final product readiness. Hundreds of customers have been surveyed to perfectly tailor GluCase to their needs. Our strategic partnerships are in place and we’ve already fulfilled our GluCase pre-order sales to our beta customers - we’re ready to go. Join Akibah health in changing lives.


Over thirty million people in the U.S. suffer from diabetes, making the disease a top-ten leading cause of death according to the CDC. GluCase can help save lives and, in the future, GluCase’s technology can also be implemented to help individuals with heart disease, the global leading cause of death.

Offering Summary


Company

:

Akibah Health Corporation

Corporate Address

:

5410 Duesenberg Drive, San Jose, CA 95123

Offering Minimum

:

$9,999.92

Offering Maximum

:

$1,069,999.84

Minimum Investment Amount

(per investor)

:

$99.68











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

17,857

Maximum Number of Shares Offered

:

1,910,714

Price per Share

:

$0.56

Pre-Money Valuation

:

$5,957,446.88











*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.


Perks*

Early Bird Bonus

  • Super Early Bird Bonus: 20% first 48 hours
  • Early Bird Bonus: 10% next 5 Days


Volume

  •  Free Mobile Health Revolution T-Shirt / Swag: $1,000 Minimum
  •  Free three-month GluCase subscription: $5,000 Minimum
  •  Free six-month GluCase subscription: $10,000 Minimum
  •  Free one-year GluCase subscription: $15,000 Minimum

*All perks occur after the offering is completed.


The 10% Bonus for StartEngine Shareholders

Akibah Health Corporation will offer 10% additional bonus shares for all investments that are committed by StartEngine Crowdfunding Inc. shareholders who invested over $1,000 or made at least two investments in StartEngine's own offerings.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $0.56 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $56. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Inter company debt or back payments.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$21,531.00 USD
$40,701.00 USD
Cash And Cash Equivalents
$117.00 USD
$23,605.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$0.00 USD
$0.00 USD
Long Term Debt
$129,083.00 USD
$115,663.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$54,805.00 USD
-$86,418.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Akibah Health has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Akibah Health be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Akibah Health has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Akibah Health be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Material Change in Offering

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the Akibah Health offering. Here's an excerpt describing the specifics of the change:


Akibah Health has extended their campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Funds Disbursement

almost 2 years ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Akibah Health has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Akibah Health be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

almost 2 years ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Akibah Health has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Akibah Health be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

almost 2 years ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Akibah Health has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Akibah Health be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}